SCHEMBL2010040

SCHEMBL2010040

COc1cc2c(CC(=O)O)c(C)n(C(=O)c3ccc(F)s3)c2cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.53
PTGS2 P35354 3/20 0.53
AKR1C3 P42330 9/20 0.49
AKR1C2 P52895 9/20 0.49
LMNA P02545 3/20 0.47
CYP1A2 P05177 3/20 0.47
CYP2C9 P11712 3/20 0.47
NPSR1 Q6W5P4 3/20 0.47
CYP2D6 P10635 2/20 0.47
HIF1A Q16665 2/20 0.47
TSHR P16473 2/20 0.47
NFKB1 P19838 1/20 0.47
ABCB1 P08183 3/20 0.45
AKR1C4 P17516 2/20 0.45
AKR1C1 Q04828 2/20 0.45
KDM4E B2RXH2 2/20 0.45
PMP22 Q01453 2/20 0.45
MEN1 O00255 1/20 0.45
PTGES O14684 1/20 0.45
ABCC3 O15438 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2002337 0.92 PTGS1 (0.53) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL3002482 0.91 PTGS1 (0.52) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL2002651 0.91 PTGS1 (0.52) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL2003192 0.90 PTGS1 (0.56) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL2001716 0.90 PTGS2 (0.52) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL2008413 0.90 PTGS1 (0.67) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL2007286 0.88 PTGS1 (0.50) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL3001453 0.88 PTGS1 (0.50) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL2005350 0.88 PTGS1 (0.50) PTGS1PTGS2AKR1C3AKR1C2LMNA
SCHEMBL2006002 0.88 PTGS1 (0.49) PTGS1PTGS2AKR1C3AKR1C2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
EP-2610244-A1 Indole compounds Ironwood Pharmaceuticals, Inc. (US) 2013-07-03 EP disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20070203209-A1 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. 2007-08-30 US disclosed
US-20070161698-A1 Modulators of CRTH2 Activity MICROBIA, INC. 2007-07-12 US disclosed
US-7205329-B2 Modulators of CRTH2 activity MICROBIA, INC. (US) 2007-04-17 US disclosed
US-20060135591-A1 Modulators of CRTH2 activity IRONWOOD PHARMACEUTICALS, INC. 2006-06-22 US disclosed
US-20050234030-A1 Modulators of CRTH2, COX-2 and FAAH IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135591-A1 Modulators of CRTH2 activity HRH2, HRH1, MRGPRX2 PTGS1 189/4885PTGS2 110/4885AKR1C3 3064/4885
US-20070161698-A1 Modulators of CRTH2 Activity HRH2, HRH1, MRGPRX2 PTGS1 189/4885PTGS2 110/4885AKR1C3 3064/4885
US-20100197708-A1 INDOLE COMPOUNDS IDO1, IDO2, TPH2 PTGS1 34/4885PTGS2 45/4885AKR1C3 1274/4885
US-20070203209-A1 Useful indole compounds TPH2, HRH2, HRH1 PTGS1 159/4885PTGS2 67/4885AKR1C3 1451/4885
US-20090264653-A1 USEFUL INDOLE COMPOUNDS FAAH, FAAH2, AANAT PTGS1 363/4885PTGS2 460/4885AKR1C3 970/4885
US-20050234030-A1 Modulators of CRTH2, COX-2 and FAAH FAAH2, FAAH, PTGES2 PTGS1 14/4885PTGS2 7/4885AKR1C3 1303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.